MedCap AB (OSTO:MCAP) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MCAP MedCap AB OSTO:MCAP
96 GF Score
Price kr533.50
GF Value kr576.67
Valuation Fairly Valued
View Full Analysis

What is MedCap AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MedCap AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr88 Mil. MedCap AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr370 Mil. MedCap AB's annualized EBITDA for the quarter that ended in Jun. 2026 was kr595 Mil. MedCap AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.77.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MedCap AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:MCAP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.76   Med: 1.49   Max: 4.47
Current: 0.85

During the past 13 years, the highest Debt-to-EBITDA Ratio of MedCap AB was 4.47. The lowest was 0.76. And the median was 1.49.

OSTO:MCAP's Debt-to-EBITDA is ranked better than
64.33% of 471 companies
in the Medical Devices & Instruments industry
Industry Median: 1.64 vs OSTO:MCAP: 0.85

MedCap AB  (OSTO:MCAP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


MedCap AB Debt-to-EBITDA Related Terms


MedCap AB Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for MedCap AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedCap AB Debt-to-EBITDA Chart

MedCap AB Annual Data
Trend Apr16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MedCap AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OSTO:MCAP vs ABT, SYK, MDT: Debt-to-EBITDA Comparison

For the Medical Devices subindustry, MedCap AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedCap AB Debt-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MedCap AB's Debt-to-EBITDA falls into.


OSTO:MCAP
96GF Score
MedCap AB OSTO:MCAP
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedCap AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MedCap AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(102.2 + 380.7) / 453
=1.07

MedCap AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(87.6 + 370) / 595.2
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is MedCap AB (OSTO:MCAP) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of kr533.50 is trading 7.5% below its estimated GF Value™ of kr576.67. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for OSTO:MCAP:

  • Debt-to-EBITDA:
  • GF Value™: kr576.67 vs. price of kr533.50 (7.5% below fair value)
  • GF Score™: 96/100

No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MedCap AB Business Description

Other Exchanges MCAPs:UK61MA:Germany
Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
96GF Score

Get the complete analysis for OSTO:MCAP

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr533.50
Price
kr576.67
GF Value